Evidence map›Paper›PMID 27989576›Full record

ArticleThe lancet. HIV2017

Population levels and geographical distribution of HIV RNA in rural Ugandan and Kenyan communities, including serodiscordant couples: a cross-sectional analysis.

Vivek Jain, Maya L Petersen, Teri Liegler, Dathan M Byonanebye, Dalsone Kwarisiima, Gabriel Chamie, Norton Sang, Doug Black, Tamara D Clark, Andras Ladai and 9 more

Erratum issued Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in The lancet. HIV, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT01864603 (Sustainable East Africa Research in Community Health), which is not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01864603 nacompletednot on this map

Sustainable East Africa Research in Community Health

TypeinterventionalSponsorUniversity of California, San FranciscoRan2013 to 2021Enrolled150,395ConditionsHIV, Tuberculosis, Hypertension, DiabetesArmsUniversal ART in a streamlined care model, Annual Community Health Campaigns, Targeted PrEP and Targeted testing interventions, Baseline community-based HIV and multi-disease testing
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Treatment as Prevention: Concepts and Challenges for Reducing HIV Incidence.Journal of acquired immune deficiency syndromes (1999) · 2019
    Article
  10. Article
  11. Article
  12. Isoniazid Preventive Therapy Completion in the Era of Differentiated HIV Care.Journal of acquired immune deficiency syndromes (1999) · 2017
    Article
  13. Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 3 countries.

Vivek JainDivision of HIV, Infectious Diseases and Global Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, USA. Electronic address: vivek.jain@ucsf.edu.
Maya L PetersenBerkeley School of Public Health, University of California, Berkeley, CA, USA.
Teri LieglerDivision of HIV, Infectious Diseases and Global Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, USA.
Dathan M ByonanebyeMakerere University and University of California, San Francisco, Research Collaboration, Kampala, Uganda.
Dalsone KwarisiimaMakerere University and University of California, San Francisco, Research Collaboration, Kampala, Uganda.
Gabriel ChamieDivision of HIV, Infectious Diseases and Global Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, USA.
Norton SangKenya Medical Research Institute, Nairobi, Kenya.
Doug BlackDivision of HIV, Infectious Diseases and Global Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, USA.
Tamara D ClarkDivision of HIV, Infectious Diseases and Global Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, USA.
Andras LadaiDivision of HIV, Infectious Diseases and Global Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, USA.
Albert PlentyDivision of HIV, Infectious Diseases and Global Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, USA.
Jane KabamiMakerere University and University of California, San Francisco, Research Collaboration, Kampala, Uganda.
Emmanuel SsemmondoMakerere University and University of California, San Francisco, Research Collaboration, Kampala, Uganda.
Elizabeth A BukusiKenya Medical Research Institute, Nairobi, Kenya.
Craig R CohenKenya Medical Research Institute, Nairobi, Kenya.
Edwin D CharleboisDivision of HIV, Infectious Diseases and Global Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, USA.
Moses R KamyaSchool of Medicine, Makerere University College of Health Sciences, Kampala, Uganda; Infectious Diseases Research Collaboration, Kampala, Uganda.
Diane V HavlirDivision of HIV, Infectious Diseases and Global Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, USA.
SEARCH Collaboration
University of California, San Francisco · USSan Francisco General Hospital · USKenya Medical Research Institute · KEMakerere University · UGUniversity of California, Berkeley · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Sheri Ann Lippman · 2001 to 2026
$57.4M
Reducing Failure-to-Initiate ART: Streamlined ART Start Strategy (START)U01AI099959 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAVLIR, DIANE V · 2012 to 2016
$39.7M
San Francisco Vaccine and Prevention UnitUM1AI069496 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · PI Susan Buchbinder, Diane V Havlir · 2012 to 2026
$30.5M
Clinical and Transtional Science InstituteKL2TR000143 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$11.9M
UCSF HIV Clinical Trials UnitU01AI069502 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAVLIR, DIANE V · 2007 to 2011
$6.1M
NCATS NIH HHS KL2 TR000143NIAID NIH HHS P30 AI027763NIAID NIH HHS U01 AI069502NIAID NIH HHS U01 AI099959NIAID NIH HHS UM1 AI069496NIMH NIH HHS P30 MH062246
6 · The paper itself

Abstract

backgroundAs sub-Saharan Africa transitions to a new era of universal antiretroviral therapy (ART), up-to-date assessments of population-level HIV RNA suppression are needed to inform interventions to optimise ART delivery. We sought to measure population viral load metrics to assess viral suppression and characterise demographic groups and geographical locations with high-level detectable viraemia in east Africa.

methodsThe Sustainable East Africa Research in Community Health (SEARCH) study is a cluster-randomised controlled trial of an HIV test-and-treat strategy in 32 rural communities in Uganda and Kenya, selected on the basis of rural setting, having an approximate population of 10 000 people, and being within the catchment area of a President's Emergency Plan for AIDS Relief-supported HIV clinic. During the baseline population assessment in the SEARCH study, we did baseline HIV testing and HIV RNA measurement. We analysed stable adult (aged ≥15 years) community residents. We defined viral suppression as a viral load of less than 500 copies per mL. To assess geographical sources of transmission risk, we established the proportion of all adults (both HIV positive and HIV negative) with a detectable viral load (local prevalence of viraemia). We defined transmission risk hotspots as geopolitical subunits within communities with an at least 5% local prevalence of viraemia. We also assessed serodiscordant couples, measuring the proportion of HIV-positive partners with detectable viraemia. The SEARCH study is registered with ClinicalTrials.gov, number NCT01864603.

findingsBetween April 2, 2013, and June 8, 2014, of 303 461 stable residents, we enumerated 274 040 (90·3%), of whom 132 030 (48·2%) were adults. Of these, 117 711 (89·2%) had their HIV status established, of whom 11 964 (10·2%) were HIV positive. Of these, we measured viral load in 8828 (73·8%) people. Viral suppression occurred in 3427 (81·6%) of 4202 HIV-positive adults on ART and 4490 (50·9%) of 8828 HIV-positive adults. Regional viral suppression among HIV-positive adults occurred in 881 (48·2%) of 1827 people in west Uganda, 516 (45·0%) of 1147 in east Uganda, and 3093 (52·8%) of 5854 in Kenya. Transmission risk hotspots occurred in three of 21 parishes in west Uganda and none in east Uganda and in 24 of 26 Kenya geopolitical subunits. In Uganda, 492 (2·9%) of 16 874 couples were serodiscordant: in 287 (58·3%) of these couples, the HIV-positive partner was viraemic (and in 69 [14·0%], viral load was >100 000 copies per mL). In Kenya, 859 (10·0%) of 8616 couples were serodiscordant: in 445 (53·0%) of these couples, the HIV-positive partner was viraemic (and in 129 [15%], viral load was >100 000 copies per mL).

interpretationBefore the start of the SEARCH trial, 51% of east African HIV-positive adults had viral suppression, reflecting ART scale-up efforts to date. Geographical hotspots of potential HIV transmission risk and detectable viraemia among serodiscordant couples warrant intensified interventions.

fundingNational Institute of Allergy and Infectious Diseases (National Institutes of Health) and the President's Emergency Plan for AIDS Relief.

Indexed as

Viral LoadAdultAnti-HIV AgentsCross-Sectional StudiesFemaleHIV-1HIV InfectionsHumansKenyaRNA, ViralRural HealthSexual PartnersUgandaAnti-HIV AgentsRNA, Viral

Identifiers

PMID27989576
PMCPMC5730457
OpenAlexW2563519897

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.